{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Electromed, Inc.
Electromed, Inc. Hits New 52-Week High of $39.35, Up 468.6%
Electromed, Inc. has achieved a new 52-week high, reflecting a substantial increase in its stock price over the past year. The company, with a market capitalization of USD 197 million, demonstrates strong financial health through its P/E ratio, return on equity, and other key metrics, indicating robust growth potential.
Electromed, Inc. Hits New 52-Week High of $39.20, Up 453%
Electromed, Inc. has achieved a new 52-week high, reflecting a substantial increase in stock performance over the past year, significantly surpassing the S&P 500. With a market capitalization of USD 197 million, the company demonstrates strong financial metrics, including a P/E ratio of 22.00 and a return on equity of 20.11%.
Electromed, Inc. Hits New 52-Week High of $38.99, Up 458%
Electromed, Inc. has achieved a new 52-week high, reflecting a substantial increase in stock performance over the past year. The company, with a market capitalization of USD 197 million, demonstrates strong profitability through a return on equity of 20.11% and a P/E ratio of 22.00.
Electromed Stock Forms Golden Cross, Signaling Potential Bullish Breakout
Electromed, Inc. has recently achieved a Golden Cross, indicating a potential shift in market momentum. While the stock has underperformed year-to-date, it has shown significant growth over the past three and five years. Current indicators suggest a bullish trend in the short term, attracting investor attention.
Is Electromed, Inc. technically bullish or bearish?
As of September 12, 2025, Electromed, Inc. shows a neutral trend with mixed technical indicators, having outperformed the S&P 500 over the past year but underperformed year-to-date, suggesting a cautious outlook.
Is Electromed, Inc. overvalued or undervalued?
As of August 26, 2025, Electromed, Inc. is fairly valued with a P/E ratio of 25 and an EV to EBITDA of 16.14, indicating it is priced at a premium compared to some peers, despite its previous attractive rating.
Is Electromed, Inc. overvalued or undervalued?
As of February 19, 2025, Electromed, Inc. is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 25, an EV to EBITDA of 16.14, a PEG ratio of 0.38, a strong ROCE of 31.20%, and a 48.39% return over the past year, outperforming the S&P 500.
Is Electromed, Inc. technically bullish or bearish?
As of May 5, 2025, the technical trend has shifted to mildly bearish due to bearish signals from the MACD, moving averages, and Bollinger Bands, despite a bullish weekly RSI.
Who are in the management team of Electromed, Inc.?
As of March 2022, the management team of Electromed, Inc. includes Independent Chairman Mr. Stephen Craney, President and CEO Ms. Kathleen Skarvan, and several Independent Directors: Mr. Stan Erickson, Mr. Gregory Fluet, Ms. Lee Jones, Ms. Andrea Walsh, and Dr. George Winn. They oversee the company's strategic direction and governance.
What does Electromed, Inc. do?
Electromed, Inc. develops and markets airway clearance products using High Frequency Chest Wall Oscillation therapy, with recent net sales of $16 million and a market cap of $168.31 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.
How big is Electromed, Inc.?
As of Jun 18, Electromed, Inc. has a market capitalization of 168.31 million and reported net sales of 61.43 million with a net profit of 7.16 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
